How did PALI's operating expenses trend in Q4 2024?

Palisade Bio Inc's operating expenses for Q4 2024 are not currently available. However, the company reported a quarterly adjusted loss of $1.55 per share for the quarter ended December 31, 2024, which is higher than the same quarter last year when the company reported an EPS of $-6.45. This suggests that while the company's losses have decreased, it may indicate that the company is still facing significant expenses. 1. **Comparison with Previous Quarters**: The company's financials for previous quarters show a beat in Q3 2024 with a loss of $2.32 compared to the estimate of $-3.35, and a beat in Q2 2024 with a loss of $-3.32 compared to the estimate of $-2.93. This indicates a improving trend in the company's financial performance, but the Q4 results show a slight setback. 2. **Revenue and Financial Outlook**: The company reported zero revenue for the quarter, which is in line with the expectations of analysts. The lack of revenue, along with the operating expenses, contributes to the company's net loss. The company's financial statements do not provide a detailed breakdown of operating expenses, so it is difficult to analyze the trend of individual expense categories. 3. **Cash Position and Recent Financing**: The company's cash position is not disclosed in the report. However, the company recently closed a $5 million public offering to fund clinical trials and research efforts. This financing could provide the company with the necessary capital to cover its operating expenses and support its ongoing research and development activities. In conclusion, while the company has shown an improving trend in its financial performance, the Q4 results indicate that the company still faces significant expenses. The lack of detailed information on operating expenses makes it difficult to analyze the trend of individual expense categories. The company's recent financing could provide the necessary capital to support its operations and research initiatives.